{
  "eval_id": "S28",
  "timestamp": "2025-09-19T09:03:42.318847+00:00",
  "model": "gpt-4o",
  "temperature": 0.6,
  "rep_input": "Patient HR+/HER2- progressed after CDK4/6; what key label-based caveats should I discuss?",
  "model_output": "For a patient with HR+/HER2- breast cancer who has progressed after CDK4/6 inhibitors, consider discussing the available treatment options that are on-label for this setting. Focus on the goals of therapy, side effect profiles, and any specific contraindications or precautions mentioned in the SmPC. Please send the relevant SmPC or EPAR by email for precise details."
}